Pharma BD Deal Intelligence
A $1.5B all-stock acquisition that never delivered the promised blockbuster: MedImmune bought Aviron for FluMist, which management pegged at $800M–$1B in peak sales but instead posted no recordable 2003 revenue and didn't clear $100M annually for roughly a decade. It survives today only as a marginal product.
A $1.5B bet on a single vaccine that never became the blockbuster it was priced for — and was still limping along as a niche product 20+ years later
Full analysis, sources & comparables →MedImmune CEO David Mott: adding FluMist to Synagis could let MedImmune 'join the elite group of biotechnology companies with more than one product' with…
MedImmune fattens its pipeline by buying Aviron; the deal is highly dilutive in 2002, neutral in 2003, accretive in 2004 - executives reduced 2002 EPS guidance…
MedImmune acquired Aviron for $1.6B in January 2002 to obtain FluMist; AstraZeneca later acquired MedImmune for $15.6B in 2007.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
MedImmune acquired Aviron in January 2002 in an all-stock transaction valued at approximately $1.5 billion, gaining FluMist, the first intranasal live-attenuated influenza vaccine. The acquisition diversified MedImmune's portfolio beyond its lead product Synagis, and the company brought FluMist to the U.S. market in 2003. Wall Street reacted negatively to the near-term dilution, sending MedImmune shares lower on the news.
A $1.5B bet on a single vaccine that never became the blockbuster it was priced for — and was still limping along as a niche product 20+ years later
Assessment window: 15yr post-close.
40M US cases/yr
Seasonal influenza causes 40-51 million illnesses, 470,000-710,000 hospitalizations and 28,000-45,000 deaths annually in the United States, with elderly, pediatric and immunocompromised populations at highest risk. Annual vaccination is the primary public-health control measure, but uptake has historically been hampered by injection aversion and reformulation requirements each season.
When the MedImmune-Aviron deal closed in January 2002, the global influenza vaccine market was a roughly $1B category dominated by inactivated injected vaccines: Aventis Pasteur's Fluzone, Wyeth's FluShield, and Chiron/Evans Fluvirin. Aviron contributed FluMist, a live attenuated cold-adapted influenza vaccine (LAIV) delivered intranasally - the first needle-free flu vaccine. FDA approved FluMist for healthy individuals aged 5-49 in June 2003. MedImmune CEO David Mott projected blockbuster potential: 'FluMist has the potential to be a blockbuster product, eventually generating more than $1 billion in peak worldwide annual sales' (MedImmune 2002 Annual Report, http://media.corporate-ir.net/media_files/IROL/83/83037/reports/ar02.pdf). Analysts noted the deal was earnings-dilutive in 2002 but would be neutral in 2003 and accretive from 2004. In practice, FluMist underperformed initial forecasts due to narrow indication, refrigeration requirements, and pricing premium versus injectable competitors; AstraZeneca later acquired MedImmune for $15.6B in 2007. The transaction nonetheless established MedImmune as the leading US biotech vaccine pure-play of the early 2000s.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| MedImmune Inc. / Aviron (this deal) | 2002 | $1.5B | 28 |
| MedImmune Inc. / Aviron | 2001 | $1.5B | 36 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
← Browse all deals · How we score deals
More: 2002 deals